middle.news
Avecho Surpasses Recruitment Target Ahead of Key Phase III Interim Analysis
9:06am on Wednesday 29th of April, 2026 AEST
•
Healthcare
Read Story
Avecho Surpasses Recruitment Target Ahead of Key Phase III Interim Analysis
9:06am on Wednesday 29th of April, 2026 AEST
Key Points
244 patients recruited, 16% above interim target
Independent Data Monitoring Board engaged for June review
Sandoz AG holds Australian commercial rights with milestone payments
Cash runway of nearly five quarters supports trial progression
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE